Purpose: The Subcommittee on Mental Health Statistics will continue discussion of enrollment and encounter minimum data sets, and receive updates on National Health Interview Survey activities with respect to mental health.

Contact Person for More Information: Gail F. Fisher, Ph.D., Executive Secretary, NCVH, NCHS, CDC, Room 1100, Presidential Building, 5625 Belcrest Road, Hyattsville, Maryland 20702, telephone 301/436-7050.

Dated: August 9, 1995.
Carolyn J. Russell, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95–20106 Filed 8–14–95; 8:45 am] BILLING CODE 4163–18–M

Food and Drug Administration

[Docket No. 95N–0247]

Drug Export; DILAUDID HP–PLUS (Hydromorphone Hydrochloride) 20 Milligram (mg)/Milliliter (mL) Vials and DILAUDID XP (Hydromorphone Hydrochloride) 50mg/mL Vials for Injection

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Knoll Pharmaceutical Co. has filed an application requesting approval for the export of the human drug DILAUDID HP–PLUS (hydromorphone hydrochloride) 20mg/mL Vials and DILAUDID XP (hydromorphone hydrochloride) 50mg/mL Vials for Injection to Canada. This product is used for the relief of severe pain in patients who require subcutaneously, intravenously, or intramuscularly administered opioids in doses or concentrations higher than those usually needed.

Dated: August 9, 1995.
Betty L. Jones, Deputy Director, Office of Compliance, Center for Drug Evaluation and Research.

[FR Doc. 95–20187 Filed 8–14–95; 8:45 am] BILLING CODE 4160–01–F

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Meeting

Pursuant to Public Law 92–463, notice is hereby given of the meetings of